Trial Profile

A Phase Ib/II Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 10 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Mosunetuzumab (Primary) ; Tiragolumab (Primary) ; Tocilizumab
Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors Roche

04 Oct 2024 Status changed from completed to discontinued, due to Sponsor decision
29 Feb 2024 Status changed from active, no longer recruiting to completed.
26 Oct 2023 This trial has been completed in Belgium (Global end date: 16 Oct 2023).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com